RU2378008C2 - Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку - Google Patents

Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку Download PDF

Info

Publication number
RU2378008C2
RU2378008C2 RU2004136295/15A RU2004136295A RU2378008C2 RU 2378008 C2 RU2378008 C2 RU 2378008C2 RU 2004136295/15 A RU2004136295/15 A RU 2004136295/15A RU 2004136295 A RU2004136295 A RU 2004136295A RU 2378008 C2 RU2378008 C2 RU 2378008C2
Authority
RU
Russia
Prior art keywords
antigen
composition according
carrier protein
conjugated
composition
Prior art date
Application number
RU2004136295/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004136295A (ru
Inventor
Дерек Томас О`ХЭЙГАН (US)
Дерек Томас О`ХЭЙГАН
Original Assignee
Новартис Вэксинес Энд Дайэгностикс С.Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Вэксинес Энд Дайэгностикс С.Р.Л. filed Critical Новартис Вэксинес Энд Дайэгностикс С.Р.Л.
Publication of RU2004136295A publication Critical patent/RU2004136295A/ru
Application granted granted Critical
Publication of RU2378008C2 publication Critical patent/RU2378008C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2004136295/15A 2002-05-14 2003-05-14 Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку RU2378008C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38067502P 2002-05-14 2002-05-14
US60/380,675 2002-05-14

Publications (2)

Publication Number Publication Date
RU2004136295A RU2004136295A (ru) 2006-03-20
RU2378008C2 true RU2378008C2 (ru) 2010-01-10

Family

ID=29420626

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004136295/15A RU2378008C2 (ru) 2002-05-14 2003-05-14 Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку

Country Status (12)

Country Link
US (2) US20060147466A1 (cg-RX-API-DMAC7.html)
EP (1) EP1506007B1 (cg-RX-API-DMAC7.html)
JP (2) JP4662537B2 (cg-RX-API-DMAC7.html)
CN (2) CN1816350B (cg-RX-API-DMAC7.html)
AT (1) ATE513560T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003239744B2 (cg-RX-API-DMAC7.html)
BR (1) BR0310042A (cg-RX-API-DMAC7.html)
CA (1) CA2485999C (cg-RX-API-DMAC7.html)
MX (1) MXPA04011248A (cg-RX-API-DMAC7.html)
NZ (1) NZ536859A (cg-RX-API-DMAC7.html)
RU (1) RU2378008C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003094960A2 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619176C2 (ru) * 2011-05-11 2017-05-12 Чилдрен'С Медикал Сентер Корпорейшн Иммуногенная композиция презентации множественных антигенов, относящиеся к ней способы и применения
RU2704452C1 (ru) * 2019-04-22 2019-10-28 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства Способ получения вакцины гемофильной тип b конъюгированной
US11013793B2 (en) 2018-09-12 2021-05-25 Affinivax, Inc. Multivalent pneumococcal vaccines
US11612647B2 (en) 2017-06-23 2023-03-28 University Of Maryland, Baltimore Immunogenic compositions
US12036276B2 (en) 2021-09-09 2024-07-16 Affinivax, Inc. Multivalent pneumococcal vaccines
US12129283B2 (en) 2018-09-12 2024-10-29 The Children's Medical Center Corporation Pneumococcal fusion protein vaccines
RU2865485C2 (ru) * 2021-03-30 2026-07-06 Дзе Юниверсити Оф Токио Вакцина с наногелевым покрытием

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
EP2269638A3 (en) * 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008101349A1 (en) 2007-02-23 2008-08-28 Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence Recombinant viral vectors for prevention and protection against alphavirus infection
CN101249261B (zh) * 2008-03-18 2010-10-27 中国疾病预防控制中心病毒病预防控制所 一种肾综合征出血热粘膜免疫疫苗及其制备方法
EP2440251A4 (en) * 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN104383531A (zh) * 2014-11-18 2015-03-04 北京智飞绿竹生物制药有限公司 预防儿童脑膜炎的联合疫苗及其制备方法
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN105031644A (zh) * 2015-06-25 2015-11-11 中国科学院过程工程研究所 一种疫苗佐剂及含该疫苗佐剂的疫苗组合物和疫苗制剂
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3185429A1 (en) * 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
RU2105568C1 (ru) * 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
WO1999042130A1 (en) * 1998-02-23 1999-08-26 Connaught Laboratories Limited Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO2002000249A2 (en) * 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0994723A1 (en) * 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
DE69939943D1 (de) * 1998-10-21 2009-01-02 Kitasato Inst Attenuierte Toxine als Adjuvantien
CA2366152A1 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
JP3980884B2 (ja) * 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ES2339762T3 (es) * 2002-01-14 2010-05-25 Novartis Vaccines And Diagnostics, Inc. Vacuna contra el vih y procedimiento de uso.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
RU2105568C1 (ru) * 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
WO1999042130A1 (en) * 1998-02-23 1999-08-26 Connaught Laboratories Limited Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO2002000249A2 (en) * 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PORRO M, A molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for gram-positive and gram-negative encapsulated bacteria. MOLECULAR IMMUNOL., v.23, №4, 1986, p.385-391. UGOZZOLI M, Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant" JOURNAL OF INFECTIOUS DISEASES, vol. 183, no. 2, 15 January 2001 (2001-01-15), pages 351-354, PMID: 11110644. GIULIANI M.M., Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity" J EXP MED, 06.04.1998; 187(7): 1123-32, PMID: 9529328. *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976097B2 (en) 2011-05-11 2024-05-07 Children's Medical Center Corporation Modified biotin-binding protein, fusion proteins thereof and applications
US10017548B2 (en) 2011-05-11 2018-07-10 Children's Medical Center Corporation Modified biotin-binding protein, fusion proteins thereof and applications
US12545710B2 (en) 2011-05-11 2026-02-10 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
US10611805B2 (en) 2011-05-11 2020-04-07 Children's Medical Center Corporation Modified biotin-binding protein, fusion proteins thereof and applications
US10766932B2 (en) 2011-05-11 2020-09-08 The Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
US11981708B2 (en) 2011-05-11 2024-05-14 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
US11560410B2 (en) 2011-05-11 2023-01-24 Children's Medical Center Corporation Modified biotin-binding protein, fusion proteins thereof and applications
RU2619176C2 (ru) * 2011-05-11 2017-05-12 Чилдрен'С Медикал Сентер Корпорейшн Иммуногенная композиция презентации множественных антигенов, относящиеся к ней способы и применения
US11612647B2 (en) 2017-06-23 2023-03-28 University Of Maryland, Baltimore Immunogenic compositions
US11701416B2 (en) 2018-09-12 2023-07-18 Affinivax, Inc. Multivalent pneumococcal vaccines
US11013793B2 (en) 2018-09-12 2021-05-25 Affinivax, Inc. Multivalent pneumococcal vaccines
US12129283B2 (en) 2018-09-12 2024-10-29 The Children's Medical Center Corporation Pneumococcal fusion protein vaccines
US12370247B2 (en) 2018-09-12 2025-07-29 Affinivax, Inc. Multivalent pneumococcal vaccines
RU2704452C1 (ru) * 2019-04-22 2019-10-28 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства Способ получения вакцины гемофильной тип b конъюгированной
RU2865485C2 (ru) * 2021-03-30 2026-07-06 Дзе Юниверсити Оф Токио Вакцина с наногелевым покрытием
US12036276B2 (en) 2021-09-09 2024-07-16 Affinivax, Inc. Multivalent pneumococcal vaccines
US12377140B2 (en) 2021-09-09 2025-08-05 Affinivax, Inc. Multivalent pneumococcal vaccines

Also Published As

Publication number Publication date
WO2003094960A3 (en) 2004-03-04
MXPA04011248A (es) 2005-02-17
US20060147466A1 (en) 2006-07-06
CA2485999C (en) 2015-02-17
CN1816350A (zh) 2006-08-09
BR0310042A (pt) 2005-04-05
US20110159030A1 (en) 2011-06-30
CA2485999A1 (en) 2003-11-20
AU2003239744A1 (en) 2003-11-11
AU2003239744B2 (en) 2008-07-03
RU2004136295A (ru) 2006-03-20
JP2010202672A (ja) 2010-09-16
EP1506007A2 (en) 2005-02-16
CN1816350B (zh) 2010-11-10
EP1506007B1 (en) 2011-06-22
JP4662537B2 (ja) 2011-03-30
NZ536859A (en) 2007-11-30
ATE513560T1 (de) 2011-07-15
CN1684707A (zh) 2005-10-19
JP2005526847A (ja) 2005-09-08
CN1684707B (zh) 2012-09-05
WO2003094960A2 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
JP4662537B2 (ja) 細菌性髄膜炎に関する粘膜組合せワクチン
JP4696260B2 (ja) キトサンアジュンバントおよび髄膜炎菌抗原を用いる粘膜ワクチン
JP7275277B2 (ja) ストレプトコッカス・ニューモニエ多糖-タンパク質コンジュゲートを含む組成物およびその使用方法
JP5075317B2 (ja) 莢膜性多糖類の可溶化および組合せワクチン
JP2010209122A (ja) キトサンアジュンバントおよび髄膜炎菌抗原を用いる粘膜ワクチン
JP2020514326A (ja) 肺炎連鎖球菌多糖−タンパク質コンジュゲートの免疫原性の増強
JP2002508761A (ja) Bordetella pertussis線毛を含有するワクチン接種結合体および経口ワクチンにおけるキャリアとしてのbordetella pertussis抗原
JP2001527050A (ja) ワクチン
JP5718545B2 (ja) 髄膜炎菌結合体ワクチン接種
HK1214129A1 (zh) 用於缀合疫苗的经过修饰的多糖
Fattom et al. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides
JP2018518512A (ja) 多価肺炎球菌コンジュゲートワクチン
US20030099672A1 (en) Pneumococcus polysaccharide conjugates for use as vaccine against tetanus an diphtheria
CN114025784A (zh) 用针对肺炎链球菌血清型29进行保护的免疫原性组合物治疗患者的方法
Fattom Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man
WO2002007764A1 (en) Improvements relating to vaccines containing bordetella pertussis antigen
JP2006516609A (ja) 粘膜髄膜炎菌性ワクチン
Moingeon Challenges and Opportunities in the Development of New Conjugate Vaccines against Infectious Diseases

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170515